CTSO - CytoSorbents Corp Stock Price, Fair Value and News

0.81USD0.00 (0.00%)Market Closed

Market Summary

USD0.810.00

Market Closed

0.00%

CTSO Stock Price

View Fullscreen

CTSO RSI Chart

CTSO Valuation

Market Cap

44.0M

Price/Earnings (Trailing)

-1.54

Price/Sales (Trailing)

1.21

EV/EBITDA

-1.18

Price/Free Cashflow

-1.98

CTSO Price/Sales (Trailing)

CTSO Profitability

EBT Margin

-80.66%

Return on Equity

-122.48%

Return on Assets

-53.52%

Free Cashflow Yield

-50.46%

CTSO Fundamentals

CTSO Revenue

Revenue (TTM)

36.3M

Rev. Growth (Yr)

-7.69%

Rev. Growth (Qtr)

-1.62%

CTSO Earnings

Earnings (TTM)

-28.5M

Earnings Growth (Yr)

-661.61%

Earnings Growth (Qtr)

36.53%

Breaking Down CTSO Revenue

Last 7 days

1.3%

Last 30 days

-12.9%

Last 90 days

-18.2%

Trailing 12 Months

-67.1%

How does CTSO drawdown profile look like?

CTSO Financial Health

Current Ratio

1.77

Debt/Equity

0.11

Debt/Cashflow

-8.52

CTSO Investor Care

Shares Dilution (1Y)

24.35%

Diluted EPS (TTM)

-0.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	35.4M	36.4M	37.1M	36.3M
2022	41.3M	37.7M	36.1M	34.7M
2021	42.9M	45.1M	44.3M	43.2M
2020	28.5M	32.0M	36.5M	41.0M
2019	22.8M	23.2M	23.6M	24.9M
2018	17.0M	19.2M	21.1M	22.5M
2017	10.8M	12.2M	13.6M	15.2M
2016	5.9M	7.1M	8.2M	9.5M
2015	3.8M	3.7M	3.9M	4.8M
2014	3.1M	3.8M	4.1M	4.1M
2013	1.7M	1.9M	2.2M	2.4M
2012	366.9K	697.8K	1.0M	1.4M
2011	216.9K	126.5K	0	36.1K
2010	0	0	0	307.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CytoSorbents Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	deliargyris efthymios	acquired	-	-	61,000	chief medical officer
Apr 02, 2024	capponi vincent	acquired	-	-	81,000	president and coo
Apr 02, 2024	chan phillip p.	acquired	-	-	96,000	chief executive officer
Apr 02, 2024	bloch kathleen p.	acquired	-	-	65,000	chief financial officer
Dec 13, 2023	bator michael g.	bought	50,000	1.33	37,594	-
Dec 13, 2023	sobel alan d.	bought	30,000	1.33	22,557	-
Dec 13, 2023	capponi vincent	bought	25,000	1.33	18,797	president & coo
Dec 13, 2023	jones edward raymond	bought	10,000	1.33	7,519	-
Dec 13, 2023	deliargyris efthymios	bought	30,000	1.33	22,557	chief medical officer
Dec 13, 2023	kim jiny	bought	10,000	1.33	7,519	-

Which funds bought or sold CTSO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Chicago Partners Investment Group LLC	reduced	-0.55	-488	26,956	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-6.00	36.00	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-57.51	-1,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-83.77	-21,436	3,458	-%
Apr 24, 2024	COUNTRY CLUB BANK /GFN	unchanged	-	-2,056	14,463	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	unchanged	-	-9,695	57,561	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	unchanged	-	-8,000	47,500	-%
Apr 18, 2024	Hexagon Capital Partners LLC	unchanged	-	-534	3,166	-%
Apr 15, 2024	Key Client Fiduciary Advisors, LLC	added	187	19,509	32,829	0.02%
Apr 10, 2024	SOA Wealth Advisors, LLC.	unchanged	-	-355	2,111	-%

Are Funds Buying or Selling CTSO?

Are funds buying CTSO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CTSO

No. of Funds

Unveiling CytoSorbents Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	granahan investment management, llc	6.93%	3,618,143	SC 13G
Feb 14, 2024	avenir corp	6.87%	3,051,402	SC 13G
Jan 08, 2024	skylands capital, llc	7.3%	3,254,213	SC 13G
Feb 14, 2023	avenir corp	5.61%	2,447,089	SC 13G/A
Feb 09, 2023	vanguard group inc	4.48%	1,956,828	SC 13G/A
Feb 07, 2023	skylands capital, llc	5.8%	2,542,091	SC 13G
Jul 08, 2022	blackrock inc.	1.7%	744,958	SC 13G
Jun 28, 2022	avenir corp	4.95%	2,156,833	SC 13G/A
Apr 25, 2022	avenir corp	5.00%	2,177,146	SC 13G
Feb 09, 2022	vanguard group inc	5.08%	2,209,165	SC 13G/A

Recent SEC filings of CytoSorbents Corp

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	DEFA14A	DEFA14A
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading

Peers (Alternatives to CytoSorbents Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

CytoSorbents Corp News

Latest updates

CytoSorbents Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-1.6%	8,668,215	8,810,847	9,420,821	9,449,496	9,390,474	8,111,353	8,495,558	8,691,424	10,782,195	9,760,416	12,024,069	10,598,847	11,955,776	10,546,612	9,794,903	8,707,310	7,430,311	6,095,007	6,232,526	5,191,629	6,080,844
Gross Profit	-5.3%	5,311,280	5,606,866	6,018,550	5,455,327	5,757,036	3,617,377	4,944,856	6,413,788	7,659,452	7,297,470	9,313,852	7,847,403	9,428,358	7,656,230	6,545,136	6,322,468	5,335,621	4,398,733	4,398,160	3,453,040	3,997,640
Operating Expenses	13.3%	14,686,104	12,957,064	12,577,787	13,346,923	12,113,392	12,634,715	13,301,906	14,204,923	17,221,274	12,703,470	14,238,585	10,699,594	12,062,623	9,615,879	9,842,803	8,801,222	10,766,949	10,026,279	8,028,157	7,738,233	9,582,906
S&GA Expenses	14.4%	9,275,047	8,104,392	7,723,952	8,463,275	7,952,892	8,735,048	8,439,367	9,160,823	10,442,710	7,776,575	9,821,490	7,709,703	8,273,530	7,282,357	6,590,903	6,316,934	6,633,194	6,107,877	4,506,516	4,758,084	6,420,590
R&D Expenses	9.3%	4,096,499	3,749,197	3,668,804	4,214,415	3,401,931	3,290,149	4,183,462	4,243,365	6,137,358	4,262,206	3,699,314	2,282,052	2,685,781	1,753,455	2,406,039	1,965,286	3,558,456	3,185,105	2,929,603	2,418,633	2,451,068
EBITDA Margin	-22.0%	-0.76	-0.62	-0.72	-0.88	-0.95	-1.14	-0.94	-0.71	-0.56	-0.36	-0.23	-0.19	-	-	-	-	-	-	-	-	-
Interest Expenses	-1.1%	101,093	102,241	102,222	71,112	-	-	-	-	-	-	-	-	243,790	298,029	266,949	318,879	327,004	274,204	230,652	227,681	223,959
Income Taxes	-	-	-	-	-	-1,092,585	-	-	-	-736,003	-	-	-	-1,127,074	-	-	-	-1,092,446	-	-	-	-619,546
Earnings Before Taxes	27.7%	-6,648,646	-9,193,520	-6,153,084	-7,325,883	-1,858,711	-12,200,837	-10,879,222	-8,966,398	-10,043,015	-6,406,285	-4,677,530	-4,167,821	-1,804,798	-839,729	-2,866,956	-3,452,779	-5,041,797	-6,885,061	-3,547,405	-4,883,827	-6,022,725
EBT Margin	-21.9%	-0.81	-0.66	-0.76	-0.91	-0.98	-1.17	-0.96	-0.73	-0.59	-0.38	-0.25	-0.23	-	-	-	-	-	-	-	-	-
Net Income	36.5%	-5,834,907	-9,193,520	-6,153,084	-7,325,883	-766,128	-12,200,837	-10,879,222	-8,966,398	-9,307,012	-6,406,285	-4,677,530	-4,167,821	-677,724	-839,729	-2,866,956	-3,452,779	-3,949,351	-6,885,061	-3,547,405	-4,883,827	-5,403,178
Net Income Margin	-24.0%	-0.78	-0.63	-0.73	-0.88	-0.95	-1.15	-0.94	-0.71	-0.57	-0.36	-0.23	-0.20	-	-	-	-	-	-	-	-	-
Free Cashflow	-21.6%	-6,502,908	-5,348,625	-6,723,838	-3,617,880	-5,553,764	-7,374,557	-12,563,917	-8,829,409	-7,024,026	-5,025,085	-2,824,861	-2,772,875	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	12.0%	53.00	48.00	52.00	57.00	63.00	62.00	71.00	83.00	90.00	95.00	98.00	87.00	90.00	104	49.00	44.00	27.00	29.00	28.00	31.00	34.00
Current Assets	33.4%	26.00	19.00	24.00	28.00	34.00	32.00	42.00	56.00	64.00	73.00	77.00	80.00	82.00	97.00	42.00	38.00	21.00	22.00	22.00	25.00	28.00
Cash Equivalents	69.1%	14.00	8.00	13.00	19.00	22.00	24.00	32.00	45.00	54.00	61.00	66.00	68.00	71.00	88.00	35.00	26.00	12.00	16.00	16.00	20.00	22.00
Inventory	23.6%	4.00	3.00	2.00	2.00	3.00	4.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00
Net PPE	-2.2%	10.00	10.00	11.00	11.00	11.00	11.00	10.00	8.00	5.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	3.2%	30.00	29.00	28.00	29.00	28.00	23.00	24.00	28.00	27.00	24.00	24.00	10.00	11.00	24.00	25.00	23.00	24.00	22.00	17.00	16.00	17.00
Current Liabilities	21.5%	15.00	12.00	10.00	10.00	10.00	10.00	11.00	15.00	14.00	11.00	11.00	10.00	10.00	17.00	16.00	11.00	10.00	9.00	7.00	7.00	7.00
Long Term Debt	-39.4%	3.00	4.00	5.00	-	5.00	-	-	-	-	-	-	-	-	6.00	8.00	11.00	13.00	12.00	9.00	8.00	9.00
LT Debt, Current	200.0%	3.00	1.00	-	-	-	-	-	-	-	-	-	-	-	9.00	7.00	4.00	2.00	3.00	1.00	2.00	1.00
LT Debt, Non Current	-39.4%	3.00	4.00	5.00	-	5.00	-	-	-	-	-	-	-	-	6.00	8.00	11.00	13.00	12.00	9.00	8.00	9.00
Shareholder's Equity	25.7%	23.00	19.00	24.00	29.00	35.00	39.00	48.00	55.00	63.00	71.00	74.00	77.00	79.00	80.00	24.00	21.00	3.00	7.00	12.00	15.00	17.00
Retained Earnings	-2.1%	-282	-276	-267	-261	-254	-253	-241	-230	-221	-211	-205	-200	-196	-195	-195	-192	-188	-184	-177	-174	-169
Additional Paid-In Capital	4.5%	305	292	290	289	287	286	285	284	283	282	281	279	278	277	219	212	192	190	189	189	186
Shares Outstanding	23.7%	54.00	44.00	44.00	44.00	44.00	44.00	44.00	43.00	43.00	43.00	43.00	43.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	144	-	61.00	-	-	-	-	-	263	-	-	-	306	-	-	-	179	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-23.1%	-6,407	-5,206	-6,933	-3,108	-5,340	-6,734	-8,039	-8,119	-5,491	-4,133	-2,036	-2,344	-1,057	-3,284	1,938	-3,209	-4,124	-5,208	-3,188	-4,237	-2,707
Share Based Compensation	-22.4%	843	1,086	570	830	869	1,005	761	787	797	999	1,558	667	650	1,088	1,046	729	491	802	145	228	1,574
Cashflow From Investing	47.3%	-135	-257	140	-682	-206	-716	-4,685	-847	-1,672	-1,017	-984	-606	-266	-404	-497	-508	-403	-315	-327	-474	-323
Cashflow From Financing	1783.4%	12,210	648	931	684	5,000	-	-	-40.36	-80.92	590	130	77.00	-15,147	56,381	7,233	17,882	773	5,220	180	2,005	475

CTSO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 36,349,379	$ 34,688,809	$ 43,165,527
Cost of revenue	13,957,356	13,955,752	11,047,350
Gross profit	22,392,023	20,733,057	32,118,177
Operating expenses:
Research and development	15,728,915	15,118,907	16,380,930
Legal, financial and other consulting	4,272,296	2,847,899	2,731,515
Selling, general and administrative	33,600,065	34,288,130	35,750,477
Total operating expenses	53,601,276	52,254,936	54,862,922
Loss from operations	(31,209,253)	(31,521,879)	(22,744,745)
Other income (expense):
Interest income (expense), net	(157,891)	132,597	28,007
Gain (loss) on foreign currency transactions	1,949,257	(2,448,583)	(2,577,913)
Miscellaneous income (expense)	96,754	(67,303)
Total other income (expense), net	1,888,120	(2,383,289)	(2,549,906)
Loss before benefit from income taxes	(29,321,133)	(33,905,168)	(25,294,651)
Benefit from income taxes	813,739	1,092,585	736,003
Net loss attributable to common stockholders	$ (28,507,394)	$ (32,812,583)	$ (24,558,648)
Basic net loss per common share	$ (0.64)	$ (0.75)	$ (0.57)
Diluted net loss per common share	$ (0.64)	$ (0.75)	$ (0.57)
Weighted average number of shares of common stock outstanding, basic	44,656,391	43,573,215	43,359,186
Weighted average number of shares of common stock outstanding, diluted	44,656,391	43,573,215	43,359,186
Comprehensive loss:
Net loss	$ (28,507,394)	$ (32,812,583)	$ (24,558,648)
Other comprehensive income (loss):
Foreign currency translation adjustment	(1,799,874)	1,803,610	2,259,663
Comprehensive loss	(30,307,268)	(31,008,973)	(22,298,985)
Total product sales
Revenue:
Total revenue	31,084,953	29,359,910	40,108,567
CytoSorb sales
Revenue:
Total revenue	31,015,268	28,572,709	39,996,700
Other product sales
Revenue:
Total revenue	69,685	787,201	111,867
Grant income
Revenue:
Total revenue	$ 5,264,426	$ 5,328,899	$ 3,056,960

CTSO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 14,131,137	$ 22,144,567
Grants and accounts receivable, net of allowances of $49,663 and $76,041 at December 31, 2023 and 2022, respectively	6,057,072	5,664,941
Inventories	3,680,129	3,461,586
Prepaid expenses and other current assets	1,834,485	2,488,597
Total current assets	25,702,823	33,759,691
Property and equipment - net	10,056,354	10,743,032
Restricted cash	1,483,958	1,687,459
Right-of-use asset	12,058,896	12,603,901
Other assets	3,958,603	4,437,447
Total Assets	53,260,634	63,231,530
Current Liabilities:
Accounts payable	3,802,170	1,655,173
Accrued expenses and other current liabilities	7,870,149	7,950,440
Lease liability - current portion	373,636	108,939
Current maturities of long-term debt	2,500,000
Total current liabilities	14,545,955	9,714,552
Lease liability, net of current portion	12,896,659	13,142,005
Long-term debt, net of current maturities	2,542,857	5,000,000
Total Liabilities	29,985,471	27,856,557
Commitments and Contingencies (Note 10)
Stockholders' Equity:
Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022
Common Stock, Par Value $0.001, 100,000,000 shares authorized; 54,240,265 and 43,635,715 shares issued and outstanding at December 31, 2023 and 2022, respectively	54,240	43,635
Additional paid-in capital	305,196,874	287,000,021
Accumulated other comprehensive income	529,321	2,329,195
Accumulated deficit	(282,505,272)	(253,997,878)
Total Stockholders' Equity	23,275,163	35,374,973
Total Liabilities and Stockholders' Equity	$ 53,260,634	$ 63,231,530

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CEO	Dr. Phillip P. Chan M.D., Ph.D.
WEBSITE	cytosorbents.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	198

CytoSorbents Corp Frequently Asked Questions

What is the ticker symbol for CytoSorbents Corp? What does CTSO stand for in stocks?

CTSO is the stock ticker symbol of CytoSorbents Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CytoSorbents Corp (CTSO)?

As of Fri Apr 26 2024, market cap of CytoSorbents Corp is 43.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTSO stock?

You can check CTSO's fair value in chart for subscribers.

What is the fair value of CTSO stock?

You can check CTSO's fair value in chart for subscribers. The fair value of CytoSorbents Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CytoSorbents Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTSO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CytoSorbents Corp a good stock to buy?

The fair value guage provides a quick view whether CTSO is over valued or under valued. Whether CytoSorbents Corp is cheap or expensive depends on the assumptions which impact CytoSorbents Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTSO.

What is CytoSorbents Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, CTSO's PE ratio (Price to Earnings) is -1.54 and Price to Sales (PS) ratio is 1.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTSO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CytoSorbents Corp's stock?

In the past 10 years, CytoSorbents Corp has provided -0.138 (multiply by 100 for percentage) rate of return.